Preliminary Results

RNS Number : 9017N
MyHealthChecked PLC
07 June 2022
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

("MyHealthChecked" or the "Company")

 

Preliminary Results

Year Ended 31 December 2021

 

MyHealthChecked PLC (AIM: MHC), the consumer home-testing healthcare company, announces its preliminary results for the year ended 31 December 2021.

 

2021 Highlights

 

Commercial

Significant revenue growth over the prior year, up from £50,000 to £16.4m

Secured agreements with the two top retail high street pharmacy chains and successfully launched and delivered into a new and unknown category

MyHealthChecked brand successfully launched and established

Over 30,000 new direct customers

Over 5,000 Trustpilot reviews to achieve a 4.3 rating at the year end

 

Portfolio and accreditation

Fast track onboarding of The Genome Store in preparation for peak COVID activity

Achieved listing on Government website/gov.uk for the COVID-19 private testing providers for general Testing and Test to Release

Acquisition of Nell Health in July 2021

UKAS stage 2 passed in January 2021 with full ISO 15189:2012 accreditation announced in September 2021

 

Operational

Migration across to new digital platform following Nell Health acquisition

Secure supply chain established successfully underpinning category volatility

Management of lean overheads

 

Financial

Adjusted EBITDA of £2.7m compared to a £2.7m loss in the prior year

Oversubscribed £3.4m (gross) share placing @ 1.75p in February 2021 which included further reinvestment by Mercia's investment funds

Cash generative for the first time with year-end cash balances of £6.4m

 

The full Group Annual Report and Financial Statements will be available shortly at www.myhealthcheckedplc.com .

 

MyHealthChecked PLC

www.myhealthcheckedplc.com

P enny McCormick, Chief Executive Officer

via Walbrook PR

Nicholas Edwards, Chief Financial Officer




SPARK Advisory Partners Limited (NOMAD)

Tel: +44 (0)20 3368 3550

Neil Baldwin




Oberon Capital Ltd (Broker)

Tel: +44 (0)203 179 5344

Mike Seabrook

mikeseabrook@oberoninvestments.com



Walbrook PR Ltd (Media & IR)

Tel: +44 (0)20 7933 8780 or myhealthcheckedplc@walbrookpr.com

Paul McManus / Alice Woodings

Mob: +44(0)7980 541 893 / +44(0)7407 804 654

 

 

About MyHealthChecked PLC ( www.myhealthcheckedplc.com )

MyHealthChecked PLC, based in Cardiff, is an AIM-quoted pioneering UK healthcare company focused on a range of at-home healthcare and wellness tests.

 

MyHealthChecked is the umbrella brand of a range of at-home DNA and RNA tests, now in development following the acquisition of The Genome Store in November 2020. The tests will be made available online, and would be viable for over the counter purchase.

 

The MyHealthChecked portfolio has been identified as part of a change in mindset as customers become more familiar with the concept of accessible healthcare in the growing at home testing kit market with a focus on accessibility at the right price, led by UK-based experts.



 

CHAIRMAN'S STATEMENT

 

2021 was a year that delivered record revenue of £16.4m and an adjusted EBITDA of £2.7m, with net cash being £6.4m at the year end.

Our key focus for 2022 will be the introduction and launch of our DNA wellbeing products in the first half of 2022. This portfolio will grow as we enter Q3 and Q4 and will be channelled initially through our Direct-to-Consumer model.

 

I would like to take this opportunity to thank all our employees who worked tirelessly during 2021 to deliver an outstanding result, not only financially but also in the quality and care of service.

 

We look forward to delivering further growth and value to shareholders in 2022 and beyond.

 

 

Adam Reynolds

Non-Executive Chairman



 

CHIEF EXECUTIVE'S REPORT AND REVIEW

 

Last year, in my first CEO review in my new role, I talked about how we had reshaped the business to deliver against an ambitious growth plan with a clear runway ahead to revenue achievement. I am proud to say that during 2021 we have delivered against this aim at every stage. MyHealthChecked has again evolved significantly over the last year, and we are well-positioned to deliver further shareholder value in 2022 as we continue to grow the business.

 

I must give due credit to our fantastic team at MyHealthChecked whose commitment and professionalism has been outstanding during an incredibly challenging time for everyone. The team adapted our business model to create a new retail product line in response to the COVID pandemic and delivered a phenomenal ramp-up of testing volume through challenging supply chain conditions. We also successfully integrated The Genome Store business during the year and acquired Nell Health Limited ("Nell Health") in July 2021. The team has delivered to an incredibly high standard, and this has been reflected in the thousands of positive customer reviews we have received, and the continuing relationships that we have established with the UK's top pharmacy retailers.

 

We have moved into 2022 in a position of strength financially, operationally and with a quickly established reputation for responsive, commercial delivery. We have exciting longer-term prospects based on a pipeline of new product introductions, whilst we continue to provide COVID testing services to our key partners, and I am delighted to update shareholders on our strong performance over the last year.

 

Successful commercial delivery - executing on our strategy for growth

The financial performance of the business is the strongest indicator of the significant step-change that we have delivered over the last year. In 2021 we recorded revenues of £16.4m (2020: £50k) and delivered an adjusted EBITDA profit of £2.7m, reversing the £2.7m adjusted EBITDA loss seen in 2020. The business has been cash generative for the first time in its history and cash balances at the year-end were £6.39m (2020: £0.47m), which reflected both good working capital management and stronger than expected cash conversion in the final quarter.

 

The main driver of commercial success was the roll-out of our new COVID-19 PCR nasal swab test kit for at-home use which was adopted by the UK's top two high street pharmacy retailers. The strong Q4 performance was also supported by the launch of our COVID-19 rapid antigen test and verification service which saw us become a distributor of FlowFlex lateral flow assays, adapting neatly with changing market needs and demonstrating our ability to successfully integrate third party products alongside our own brand.

 

Our team also supported a number of smaller travel and institutional Business-to-Business ("B2B") customers, however it is the opening up of our own Direct-to-Consumer sales channel which, supported by our investment in digital marketing and excellent customer service provision, grew to contribute approximately £2.4m to overall revenues. As the Company has grown, we have focused on the establishment of our reputable brand with a customer-first approach to both retail partners and directly with consumers. Our Care Team has worked tirelessly to ensure that our service excellence is captured, securing over 5,000 reviews on Trustpilot in 2021 and currently standing at over 7,000 at the time of writing. Our marketing strategy has been focussed on effective referral channels and pricing strategies, ensuring that we always deliver customer value.

 

Careful cost control and operational excellence

Whilst transforming the operational and commercial capacity of the business to meet market demands we have kept a tight control of our cost base and have maximised efficiencies by working closely with key suppliers and maintaining a flexible and lean team that has delivered extraordinary growth over the last 12 months.

 

We have continued to ensure that our operational footprint matches our clients' demands as well as providing the flexibility to expand for future growth as required.  The flexible arrangements at our Cardiff Head office have allowed us to scale up and scale down through the year without any detriment to the provision of customer care and dispatch. Our Manchester laboratory operation, combined with third-party supply from Yourgene Health PLC ("Yourgene"), allowed us to maintain a reputation for quality of service with reliable turnaround times that consistently met the requirements of our customers. It is a mark of the quality of the team that we were able to achieve ISO 15189 standards within six months of opening the laboratory, and we consistently achieved 100% for the reliability of patient results and accuracy of reporting in the SARS CoV-2 External Quality Assurance Programme. Our facilities were subject to ongoing review by our retail partners, and I am proud that the team have consistently met their exacting requirements. As part of an internal review however, in response to a significant downturn in COVID PCR testing and our drive to remain cost efficient, our laboratory operations will close in the current quarter whilst we continue to utilise Yourgene's laboratories, in conjunction with our in-house expertise, to continue building our scientific and digital portfolio.

 

 

Preparation for the launch of a portfolio of personalised wellness tests in H1 2022

Whilst we are still benefitting from our pivot into the provision of COVID-19 rapid antigen tests, a key focus of our business as we have moved into the new financial year has been on re-investing 2021 earnings into our new product pipeline of at-home wellness tests and building digital healthcare-centric technology that is scalable.

 

The effective integration of Nell Health, acquired in July 2021, has enabled the migration of our Laboratory Information Management System ('LIMS') onto the digital platform that will underpin the future business as it expands. Nell Health provided access to innovative technology in-house, that is secure, adaptable, and robust for future product and service developments.

 

This new scalable customer facing e-commerce platform enables connection from customer through to the lab and facilitates Government required reporting for COVID testing and has been further enhanced in readiness for the launch of future tests. We continue to focus on cyber security, and work closely with our Data Protection Officer to ensure that our systems are robust as we launch our new app technology that will provide actionable health and nutritional guidance, tailored to the customer. Our realignment of the goals and strategy of the business has included the mapping-out of a range of accessible family healthcare tests, with the aim of helping our customers to take control of their own healthcare, whilst providing a positive customer experience.

 

We remain on track to launch five new at-home wellness tests this month, focussing on the areas of weight management, vitamin deficiency, food intolerances, heart health and blood glucose. We will be announcing further portfolio developments through the course of the year to support our clear business development strategy across Direct-to-Consumer, retail, and B2B channels and I look forward to updating shareholders on this in due course.

 

We will continue to explore additional third-party technology options that can enhance the customer journey and the value of our products, and which can be integrated by our in-house talent. We also maintain our efforts to identify and assess complementary earnings-enhancing partnerships with organisations that demonstrate potential value-add and are a complementary and strategic fit to our core business.

 

Whilst COVID-19 was the number one priority for 2021, and portfolio growth is key to our long-term growth strategy, we will continue to reinforce our strong reputation in the COVID-19 testing space, providing a high-quality product and service to our key partners. We will do so whilst consistently evaluating the cost effectiveness of our operations.

 

Summary and outlook

Last year I commented that we had ended 2020 and commenced 2021 as a very different organisation to that of the previous January, and that we were poised to meet the needs of the market in 2021. I am delighted that we absolutely met the needs of the market this past year, and I am confident echoing those comments this year: that we have grown to be a very different organisation to that of January 2021, commencing 2022 in a stronger position.

 

Having pivoted the original Concepta business plan, our first year of commercial delivery has demonstrated that this was the right decision, and we have delivered a successful start in our journey to an exciting future. Whilst we did deliberately delay the launch of the wider portfolio of wellness products until the COVID market stabilised, we have in the meantime demonstrated our ability to effectively identify the right tests for the market, secure supplier and customer relationships, and manage challenging supply chains effectively, whilst remaining competitive on price, and excelling in customer service and delivery.

 

We have in place a secure digital platform, a customer base opening up to the new idea of home-testing, and an existing customer base to whom we can share our new product information.

 

2022 will be another exciting year for the business as we launch our initial portfolio of new tests and build upon our sophisticated digital platform, which presents a fantastic opportunity for us to grow and create value for our shareholders. This will be supported by positive trading in the COVID space, as over the counter consumer demand continues into 2022.

 

 

Penny McCormick

Chief Executive Officer

 



 

FINANCIAL REVIEW

 

In come statement  

Following the acquisition of The Genome Store in November 2020, the Group was able to launch the COVID-19 PCR nasal swab test kit for at-home use in December 2020 which enabled revenues to increase from £50,000 in 2020 to £16,376,000 with a gross profit margin of 31.3% in the year under review. Further details are set out in the Chief Executive's Report and Strategic Review.

 

Administration costs amounted to £3,079,000 compared to £3,118,000 in the prior year after expensed research and development expenditure of £175,000 (2020: £487,000). An impairment provision of £414,000 has also been taken in 2021 against the know-how and goodwill arising on the acquisition of The Genome Store as all testing is now sub -contracted to third parties and the testing laboratory is being closed. In 2020 the charge was £622,000.

 

Adjusted EBITDA is calculated as follows:


2021

2020


£'000

£'000

Operating profit/(loss

2,046

(3,758)

Depreciation and amortisation

157

157

Impairment provision (net of DT credit)

414

622

Share based payments

112

103

Loss on disposal of intangible assets

-

180

Adjusted EBITDA

2,729

(2,696)

 

The Group's profit before after taxation was £2,004,000 (2020: £3,763,000 loss) giving a basic earnings per share of 0.28p (2020: loss 0.89p) and fully diluted earnings per share of 0.27p.

 

Financial position

The Group's net assets at 31 December 2021 amounted to £7,113,000 (2020: £530,000). This comprised total assets of £11,668,000 (2020: £1,336,000) and total liabilities of £4,555,000 (2020: £806,000). The total assets included property, plant and equipment of £163,000 (2020: £56,000) and intangible assets, being development costs, know-how, goodwill and patent costs, of £2,289,000 (2020: £616,000). The significant additions during the year relate to the goodwill and digital platform acquired on the acquisition of Nell Health.  As noted above an impairment provision was made against the know-how and goodwill arising on the acquisition of The Genome Store which was acquired last year.

 

Cashflow

The Group's cash balance at the year-end was £6,387,000 (2020: £466,000). The net inflow from operating activities amounted to £3,014,000 (2020: £2,072,000 outflow) with a further £3,206,000 (2020: £1,960,000) net of expenses raised through financing activities, whilst the cash outflows from investing activities amounted to  £299,000 (2020: £38,000).

 

Capital management

The Board's objective is to maintain a balance sheet that is both efficient and delivers long term shareholder value. The Board continues to monitor the balance sheet to ensure it has an adequate capital structure.

 

Events after the reporting year

On 25 March 2022 24,000,000 new ordinary shares of 0.1p each were issued to settle the deferred contingent consideration payable on the acquisition of The Genome Store Limited of £240,000 after all performance milestones were met.

 

 

Nicholas Edwards

Chief Financial Officer



 

FINANCIAL STATEMENTS

 

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For The Year Ended 31 December 2021

 



2021

2020



£'000

£'000





Revenue from contracts with customers


16,376

50

Cost of sales


(11,251)

(690)

Gross profit/(loss)

 

5,125

(640)





Other administrative expenses


(2,553)

(2,213)

Impairment of intangible assets


(414)

(622)

Share based payments


(112)

(103)

Loss on disposal of tangible assets


-

(180)





Administrative expenses


(3,079)

(3,118)

Operating profit/(loss)

 

2,046

(3,758)

Finance expenses


(2)

(5)

Additional consideration payable on the

acquisition of The Genome Store Limited


(40)

-

Profit/(loss) before income tax

 

2,004

(3,763)

Tax charge


-

-

Profit/(loss) for the year

 

2,004

(3,763)

Other comprehensive income


-

-

Total comprehensive Profit/(loss) for the year

 

2,004

(3,763)





Attributable to owners of the parent:

 

2,004

(3,763)

 

 

 

 

Earnings/(loss) per ordinary share - basic

 

0.28p

(0.89p)

Fully diluted earnings per ordinary share

 

0.27p

-

 

 

All activities relate to continuing operations.



 

CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As At 31 December 2021



2021

2020



£'000

£'000

Non-current assets




Property, plant and equipment


163

56

Intangible assets


2,289

616

Total non-current assets

 

2,452

672





Current assets




Inventories


497

3

Trade and other receivables


2,332

195

Cash and cash equivalents


6,387

466

Total current assets

 

9,216

664





Total assets

 

11,668

1,336





Current liabilities




Trade and other payables


3,315

384

Deferred tax liability


-

87

Lease liabilities


-

5

Deferred consideration

 

1,240

200

Other provisions


-

26

Total current liabilities

 

4,555

702

Non-current liabilities

 

 

 

Loans and borrowings


-

104

Total non-current liabilities

 

-

104





Total liabilities

 

4,555

806

Net assets

 

7,113

530





Share capital


756

518

Deferred shares


6,359

6,359

Share premium account


16,671

12,442

Share-based payment reserve


-

916

Capital redemption reserve


1,815

1,815

Reverse acquisition reserve


(6,044)

(6,044)

Retained earnings


(12,444)

(15,476)

Total equity

 

7,113

530



 

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY


Share capital

 

 

 

Deferred

shares

 Share Premium

Share-based payment reserve

 Capital redemption reserve

Reverse acquisition

reserve

 Retained earnings

Total

 

£'000

 

£'000

£'000

£'000

 '000

 '000

£'000

£'000

Equity as at

1 January 2020

6,624

 

-

10,740

813

1,815

(6,044)

(11,713)

2,235

Loss for the year

-

 

-

-

-

-

-

(3,763)

(3,763)

Total

comprehensive loss

-

 

-

-

-

-

-

(3,763)

(3,763)

Issue of shares net of expenses

253

 

-

1,702

-

-

-

-

1,955

Share-based payments

-

 

-

-

103

-

-

-

103

Sub-division of ordinary shares to deferred shares

(6,359)

 

6,359

-

-

-

-

-

-

Equity as at

31 December 2020

518

 

6,359

12,442

916

1,815

(6,044)

(15,476)

530

Profit for the year

-

 

-

-

-

-

-

2,004

2,004

Total

comprehensive profit

-

-

-

-

-

-

2,004

2,004

Transfer from share based payment reserve

-

 

 

-

-

(916)

-

-

916

-

Issue of shares net of expenses

194

 

-

2,979

-

-

-

-

3,173

Conversion of loan note and interest

13


92

-

-

-

-

105

Exercise of options

2

-

18

-

-

-

-

20

Other share issue

1


16

-

-

-

-

17

Share-based payments

-

 

-

-

-

-

-

112

112

Acquisition of Nell Health Limited

28


1,124

-

-

-

-

1,152

Equity as at

31 December 2021

756

 

6,359

16,671

-

1,815

(6,044)

(12,444)

7,113

 



 

CONSOLIDATED STATEMENT OF CASH FLOWS

For The Year Ended 31 December 2021





2021

2020


£'000

£'000

Cash flows from operating activities



Profit/(loss) before taxation

2,004

(3,763)

Adjustments for:



Deferred consideration

40

-

(Decrease)/increase in provisions

(26)

26

Depreciation and amortization

157

157

Impairment of intangible assets

414

622

Finance expenses

2

5

Share-based payments

112

103

Loss on sale of asset

-

180

Adjusted operating profit/(loss) before changes in working capital

2,703

(2,670)

Changes in working capital

 

 

(Increase)/decrease in inventory

(494)

381

Increase in trade and other receivables

(2,124)

(72)

Increase in trade and other payables

2,931

116

Cash generated/(used) in operations

3,016

(2,245)

Tax received

-

178

Other interest

(2)

(5)

Net cash inflow/(outflow) from operating activities

3,014

(2,072)

Investing activities



Acquisition of Nell Health Limited

(50)

-

Purchase of property, plant and equipment

(147)

(35)

Purchase of intangible assets

(102)

(3)

Net cash flows used in investing activities

(299)

(38)

Financing activities



Issue of ordinary shares (net of issue expenses)

3,211

1,675

Convertible loan note

-

101

Sale of assets

-

285

Repayment of lease liability

(5)

(101)

Net cash flows from financing activities

3,206

1,960

Net change in cash and cash equivalents

5,921

(150)

Cash and cash equivalents at the beginning of the year

466

616

Cash and cash equivalents at the end of the year

6,387

466

 

 

 

 

 

 

 



 

NOTES TO THE FINANCIAL STATEMENTS

 

The notes to the Financial Statement are available in full in the Group Annual Report and Financial Statements which will be available shortly on the Company website: www.myhealthcheckedplc.com

 

Basis of preparation

The financial statements have been prepared in accordance with UK adopted international accounting standards (IFRS), and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS

 

Earnings/(loss) per share


2021

2020

Basic and diluted



Profit/(loss) for the year and earnings used in basic & diluted EPS

£2,004,000

(£3,763,000)

Weighted average number of shares - basic

710,852,000

420,757,000

Weighted average number of shares - fully diluted

744,056,000

-

Earnings/(loss) per share  

0.28p

(0.89p)

Fully diluted earnings per share

0.27p

-

 

Basic earnings per share is calculated by dividing the loss attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the year.  Due to the loss in the prior year the effect of the share options was considered anti-dilutive and hence no diluted loss per share information has been provided.

 

Events after the reporting date

On 25 March 2022 24,00,000 new ordinary shares of 0.1p were issued to settle the deferred consideration payable on the acquisition of The Genome Store Limited of £240,000 after all performance milestones were met.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FR UPUPCQUPPGQQ
UK 100

Latest directors dealings